Ignite Creation Date:
2024-05-05 @ 9:42 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002114
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Double-Blind Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides
Sponsor:
Free Radical Sciences
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Double-Blind Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides
Status:
COMPLETED
Status Verified Date:
1994-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the efficacy and safety of orally administered Procysteine with placebo in HIV-infected patients who are receiving 1 of the following 1 zidovudine AZT alone 2 didanosine ddI alone 3 AZT plus ddI or 4 AZT plus zalcitabine ddC
Detailed Description:
All patients must receive treatment with antiretroviral nucleosides in addition to study treatment Patients are randomized equally into 1 of 3 outpatient dosage groups Group 1 receives placebo Group 2 receives a low dose of Procysteine and Group 3 receives a higher dose of Procysteine Patients receive study treatment for 6 months total duration of patient participation is 30 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CN9202D | None | None | None |